Testing cadonilimab and regorafenib for liver cancer after other treatments fail
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intermediate or advanced liver cancer that has been confirmed by a biopsy or meets specific clinical guidelines.
- Your liver cancer has gotten worse after treatment with camrelizumab and apatinib.
- Your liver function is good (Child-Pugh class A) and you are in generally good health (ECOG score 0-1).
- You have at least one tumor that can be measured on a scan.
- Your blood counts and organ function (kidneys, liver) are within safe limits as checked by blood tests.
- You have no serious bleeding problems, no uncontrolled fluid buildup in the belly or chest, and no history of liver transplant or brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer whose disease progressed after or couldn't tolerate first-line immunotherapy. The goal is to see if this drug can slow or shrink the cancer.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.